Literature DB >> 6427361

In vivo activity of proteases of Pseudomonas aeruginosa in a rat model.

G Döring, A Dalhoff, O Vogel, H Brunner, U Dröge, K Botzenhart.   

Abstract

The granuloma pouch technique was used to study the in vivo characteristics of four strains of Pseudomonas aeruginosa that differed in levels of alkaline protease and elastase production. Bacterial counts, alkaline protease and elastase concentrations, and IgG levels of pouch exudates were determined quantitatively; total protein levels were determined semiquantitatively. In vivo protease concentrations were in the nanogram range; during the investigated period individual strains either increased enzyme production or remained negative. In vitro alkaline protease:elastase ratios correlated with in vivo ratios in three of the four strains. Proteolytic strains caused a decrease in IgG and alpha 2-fraction proteins. Purified rat IgG was cleaved rapidly by elastase and slowly by alkaline protease; both cleaved IgG at the hinge region. The study determines the concentration of P aeruginosa alkaline protease and elastase after infection in a rat model, shows cleavage of rat IgG and other proteins due to alkaline protease and elastase, and suggests that enzymes other than proteases are involved in the pathogenesis of P aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427361     DOI: 10.1093/infdis/149.4.532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Degradation of soluble laminin and depletion of tissue-associated basement membrane laminin by Pseudomonas aeruginosa elastase and alkaline protease.

Authors:  L W Heck; K Morihara; D R Abrahamson
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  Rapid reprogramming of haemoglobin structure-function exposes multiple dual-antimicrobial potencies.

Authors:  Ruijuan Du; Bow Ho; Jeak Ling Ding
Journal:  EMBO J       Date:  2009-12-17       Impact factor: 11.598

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation.

Authors:  B E Britigan; B L Edeker
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

5.  Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases.

Authors:  T G Theander; A Kharazmi; B K Pedersen; L D Christensen; N Tvede; L K Poulsen; N Odum; M Svenson; K Bendtzen
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

6.  Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4.

Authors:  A Buret; M Dunkley; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

7.  Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis.

Authors:  G Döring; W Goldstein; A Röll; P O Schiøtz; N Høiby; K Botzenhart
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

8.  A drug-repositioning screening identifies pentetic acid as a potential therapeutic agent for suppressing the elastase-mediated virulence of Pseudomonas aeruginosa.

Authors:  Mia Gi; Junhui Jeong; Keehoon Lee; Kang-Mu Lee; Masanori Toyofuku; Dong Eun Yong; Sang Sun Yoon; Jae Young Choi
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

9.  Iron release from transferrin by pyoverdin and elastase from Pseudomonas aeruginosa.

Authors:  C Wolz; K Hohloch; A Ocaktan; K Poole; R W Evans; N Rochel; A M Albrecht-Gary; M A Abdallah; G Döring
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  [Significance of Pseudomonas aeruginosa virulence factors for acute and chronic Pseudomonas aeruginosa infections].

Authors:  G Döring
Journal:  Infection       Date:  1987       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.